Drug Combination Details
| General Information of the Combination (ID: C91158) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Imatinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Phase 2 | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABL | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCR | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | ||
| Experimental
Result(s) |
As2O3 in combination with imatinib showed favorable cytotoxicity and proapoptotic activity in chronic myelogenous leckemia. | |||||
